Charles River Laboratories International (CRL) Long-Term Deferred Tax (2016 - 2025)
Charles River Laboratories International has reported Long-Term Deferred Tax over the past 16 years, most recently at $67.3 million for Q4 2025.
- Quarterly results put Long-Term Deferred Tax at $67.3 million for Q4 2025, up 59.64% from a year ago — trailing twelve months through Dec 2025 was $67.3 million (up 59.64% YoY), and the annual figure for FY2025 was $67.3 million, up 59.64%.
- Long-Term Deferred Tax for Q4 2025 was $67.3 million at Charles River Laboratories International, up from $36.9 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for CRL hit a ceiling of $67.3 million in Q4 2025 and a floor of $31.9 million in Q2 2021.
- Median Long-Term Deferred Tax over the past 5 years was $40.3 million (2021), compared with a mean of $41.1 million.
- Biggest five-year swings in Long-Term Deferred Tax: dropped 25.48% in 2021 and later soared 59.64% in 2025.
- Charles River Laboratories International's Long-Term Deferred Tax stood at $40.2 million in 2021, then rose by 2.58% to $41.3 million in 2022, then fell by 2.38% to $40.3 million in 2023, then rose by 4.72% to $42.2 million in 2024, then soared by 59.64% to $67.3 million in 2025.
- The last three reported values for Long-Term Deferred Tax were $67.3 million (Q4 2025), $36.9 million (Q3 2025), and $46.9 million (Q2 2025) per Business Quant data.